Insider buying
~$7.1K2,500 sh @ $2.84
Traded Nov 17 · filed 1 day later
A Nephros director paid $7.1K out of pocket for Nephros shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 16, 2026 · Filed Nov 18, 2026
A Nephros director paid $15K out of pocket for Nephros shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$14,975
Shares × reported transaction price
<$25K
+3.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
11 days after results of Nov 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $3.00 on Nov 16, 2026, 8% above its 52-week low and 48% below its high, after a 15% drop over the previous 30 trading days
52-week range $2.78 (Apr 7, 2026) to $5.79 (Dec 4, 2025), 7% of the way up, from 251 adjusted closes. 30 trading days earlier: $3.55 on Oct 5, 2026. Describes the past only, not a forecast
RSI 41, 16% under its 200-day average, 18% under its 50-day average, 48% below the 52-week high, 20-day volatility 81% a year, against the S&P 500: −15 points over 1 month, −31 points over 3 months, −19 points over 6 months
From the adjusted closes up to Nov 16, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 1 day before NEPH filed an 8-K: changed a top executive or board member (Nov 17, 2026). The first open-market purchase by any NEPH insider since May 2024. Arthur H Amron's first purchase of NEPH since May 2024
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider buying
Traded Nov 17 · filed 1 day later
A Nephros director paid $7.1K out of pocket for Nephros shares.
Insider filing
Traded Nov 9 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 9 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade. A share price line is a session where the close moved at least 10% and four times its usual daily change.
The company's last weighty Form 8-K report up to this date: reported its results, 102 days earlier (Aug 6, 2026). The first one after it: changed a top executive or board member, 1 day later (Nov 17, 2026).
Arthur H Amron, Director's past purchases, 90 days after disclosure: 4 buys, median −5.3 pts vs S&P 500, beat it 1 of 4 times. Past results, not a forecast.